Yazar "Kazezoglu, Cemal" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Arginase and Ornithine in Human Benign and Malignant Skin Tumors
    (Walter De Gruyter Gmbh, 2010) Gokmen, Selma Suer; Kazezoglu, Cemal; Aygit, A. Cemal; Yildiz, Reyhan; Cakir, Beyhan; Ture, Mevlut; Gulen, Sendogan
    Objectives: Arginase activity and ornithine concentration have been shown to be elevated in experimentally-induced benign tumors in mice. The aim of the study is to investigate arginase activity and ornithine concentration in human benign and malignant skin tumors and to evaluate their role for prognosis of skin tumors. Patients and Methods: We have investigated arginase activity and ornithine concentration in supernatant of homogenates of benign tumors (nevus) of the skin from 13 patients and of malignant tumors (squamous cell or basal cell carcinomas) from 29 patients. Total arginase activity, ornithine and total protein concentration in supernatant were determined by the methods of Geyer, Chinard and Lowry, respectively. Results: Arginase activity (p=0.006) and ornithine concentration (p=0.007) in nevus were significantly higher than in adjacent normal tissue. There was no significant difference between their levels in basal cell carcinoma and in nevus (p>0.05). There was no significant difference between ornithine concentration in squamous cell carcinoma and in nevus (p>0.05). However, arginase activity in this carcinoma was significantly higher than in nevus (p=0.018). Conclusion: The significant difference between tissue arginase activities in squamous cell carcinoma and in nevus indicates that determination of arginase activity could be useful for prognosis of skin tumors.
  • Küçük Resim Yok
    Öğe
    The Effect of Cisplatin plus Etoposide Therapy on Serum Total and Lipid-Bound Sialic Acid Levels in Patients with Non-small Cell Lung Cancer
    (Turkish Biochem Soc, 2010) Gokmen, Selma Suer; Kazezoglu, Cemal; Tabakoglu, Erhan; Gungor, Ozgul; Altiay, Gundeniz; Ture, Mevlut
    Objectives: To investigate the effect of cisplatin+etoposide therapy on serum total and lipid-bound sialic acid levels in patients with non-small cell lung cancer and evaluate the role of these parameters in the monitoring of the therapy. Patients and Methods: To 18 patients (all men) who are newly diagnosed as nonsmall cell lung cancer, cisplatin was given intravenously (80mg/m(2)) on day 1 and etoposide was given (100mg/m(2)) on day 1-3 to the patients once at an interval of 21 day. Blood samples before the first chemotherapy were compared with those obtained after the second and third chemotherapy. The percent of chemotherapy responses of patients were also calculated. Total and lipid-bound sialic levels were determined by the methods of Warren and Katopodis, respectively. Results: There was a significant decrease in serum lipid-bound sialic acid levels after the second chemotherapy when compared with those before the first chemotherapy (t=2.216, p=0.041). Positive response to cisplatin+etoposide therapy was observed in 88.89% (11.11% of total response, 44.44% of partial response and 33.33% of stable response) of the patients. Progressive disease was established in only 11.11% of the patients. It was found a statistically significant decrease in both serum total (t=2.924, p=0.017) and lipid-bound sialic acid (t=3.635, p=0.005) levels after the third chemotherapy when compared with those before the first chemotherapy. Conclusion: Determination of serum total and lipid-bound sialic acid levels besides routine applications may be useful in the monitoring of cisplatin+etoposide therapy.
  • Küçük Resim Yok
    Öğe
    The importance of serum total and lipid-bound sialic acid as markers in patients with small cell and non-small cell lung carcinoma
    (Aves Yayincilik, Ibrahim Kara, 2007) Gokmen, Selma Suer; Kazezoglu, Cemal; Tabakoglu, Erhan; Altiay, Guendeniz; Gungoer, Ozgul; Ture, Mevlut
    Objectives: Serum total sialic acid (TSA) and lipid-bound sialic acid (LSA) levels were investigated in patients with small and non-small cell lung carcinoma and their role in discriminating small from non-small cell lung carcinoma and lung carcinoma from healthy individuals was evaluated. Patients and Methods: The study included 159 male patients with non-small cell lung carcinoma (n=102) and small cell lung carcinoma (n=57) who never received chemotherapy and/or radiotherapy and 35 healthy volunteers as controls. Serum TSA and LSA levels were determined by the methods of Warren and Katopodis, respectively. Results: Serum TSA and LSA levels in both patient groups were significantly elevated when compared with controls (p < 0.001), but the patient groups did not differ significantly in this respect. Receiver operating characteristic (ROC) analysis showed that TSA was more specific and LSA was more sensitive in distinguishing patients with non-small cell carcinoma from healthy individuals. On the other hand, LSA was found to be more sensitive in distinguishing patients with small cell carcinoma from healthy controls. Conclusion: Serum total and lipid-bound sialic acid may play an important role as biochemical markers in distinguishing patients with small and non-small cell lung carcinoma from healthy subjects.
  • Küçük Resim Yok
    Öğe
    Serum total and lipid bound sialic acid levels in patients with benign and nonmelanom malignant skin tumors
    (Walter De Gruyter Gmbh, 2007) Kazezoglu, Cemal; Goekmen, Selma Sueer; Sunar, Bendigar; Aygit, Cemal; Cakir, Beyhan
    It has been reported that sialic acid containing oligosaccharides play an important role in the adhesion between cancer cells and endothelial cells and metastatic potential of tumor cells is proportional to cell surface sialylation. In the present study, we investigated whether there is a change in serum total and lipid bound sialic acid levels of patients with benign and non-melanom malignant skin tumors and, evaluated whether the measurement of sialic acid levels may be useful clinically in distinguishing patients with benign skin tumors from those with non-melanom malignant skin tumors. In this study, 27 patients with malignant skin tumors ( 16 men, age 50.78 +/- 12.46 years), 39 patients with benign skin tumors ( 17 men, age 48.59 +/- 16.23 years) were included. Serum total and lipid bound sialic acid determination was performed by the thiobarbituric acid method described by Warren and, the resorsinol method described by Katopodis, respectively. Student's T test and Z test were used to analyze the results. The mean serum total and lipid bound sialic acid levels were found to be 63.01 +/- 11.89 mg/dl and 15.77 +/- 2.44 mg/dl, respectively in patients with benign skin tumors; and 65.95 +/- 7.30 mg/dl and 16.70 +/- 3.80 mg/dl, respectively in patients with non-melanom malignant skin tumors. Serum total sialic acid and lipid bound sialic acid of patients with benign skin tumors were not different from those of patients with non-melanom malignant skin tumors. The percentage of lipid bound sialic acid was found to be 25.3 in patients with non-melanom malignant skin tumors, 25 in patients with benign skin tumors. There was no significant difference between the value of lipid bound sialic acid percentage in these groups. Our finding that there is no significant difference between serum total and lipid-bound sialic acid levels of patients with non melanom malignant skin tumors which are not able to metastase and patients with benign skin tumors supports the studies reporting that sialic acids play an important role in metastases.